Literature DB >> 3810065

Symptom monitoring in the rehabilitation of schizophrenic patients.

D Lukoff, R P Liberman, K H Nuechterlein.   

Abstract

Although precise laboratory methods for measuring psychopathology are not available, interviewer-rated instruments developed to assess symptomatology can be used to monitor schizophrenic patients undergoing rehabilitation. By regularly assessing patients, rehabilitation staff can improve the effectiveness of their interventions. Patients can be screened for high levels of symptomatology which might preclude assignment to rehabilitation programs with high levels of social stimulation. Monitoring the prodromal symptoms of relapse can sometimes prevent florid relapses and sustain a rehabilitative trajectory. Standardized instruments for measuring positive symptoms (e.g., hallucinations, delusions, and conceptual disorganization) and negative symptoms (e.g., affective blunting, amotivation, and asociality) are available. Monitoring target symptoms may be particularly cost effective in the rehabilitation milieu. Use of suggested operational criteria for defining clinical states such as relapse would improve outcome studies on rehabilitation interventions.

Entities:  

Mesh:

Year:  1986        PMID: 3810065     DOI: 10.1093/schbul/12.4.578

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  100 in total

1.  A randomized-controlled trial of intensive case management emphasizing the recovery model among patients with severe and enduring mental illness.

Authors:  S O'Brien; J McFarland; B Kealy; A Pullela; J Saunders; W Cullen; D Meagher
Journal:  Ir J Med Sci       Date:  2012-01-05       Impact factor: 1.568

2.  Evaluation of a multi-element treatment center for early psychosis in the United States.

Authors:  Sarah R Uzenoff; David L Penn; Karen A Graham; Sylvia Saade; Barbara B Smith; Diana O Perkins
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-01-26       Impact factor: 4.328

3.  Event-related potentials and changes of brain rhythm oscillations during working memory activation in patients with first-episode psychosis.

Authors:  Pascal Missonnier; François R Herrmann; Adriano Zanello; Maryse Badan Bâ; Logos Curtis; Diana Canovas; Fabrice Chantraine; Jonas Richiardi; Panteleimon Giannakopoulos; Marco C G Merlo
Journal:  J Psychiatry Neurosci       Date:  2012-02       Impact factor: 6.186

4.  The working alliance and consumer case management.

Authors:  P Solomon; J Draine; M A Delaney
Journal:  J Ment Health Adm       Date:  1995

5.  The efficacy of a consumer case management team: 2-year outcomes of a randomized trial.

Authors:  P Solomon; J Draine
Journal:  J Ment Health Adm       Date:  1995

6.  Recovery from serious mental illness: trajectories, characteristics, and the role of mental health care.

Authors:  Carla A Green; Nancy A Perrin; Michael C Leo; Shannon L Janoff; Bobbi Jo H Yarborough; Robert I Paulson
Journal:  Psychiatr Serv       Date:  2013-12-01       Impact factor: 3.084

7.  Unseen Affective Faces Influence Person Perception Judgments in Schizophrenia.

Authors:  Ann M Kring; Erika H Siegel; Lisa Feldman Barrett
Journal:  Clin Psychol Sci       Date:  2014-07

8.  Randomised controlled trial of acute mental health care by a crisis resolution team: the north Islington crisis study.

Authors:  Sonia Johnson; Fiona Nolan; Stephen Pilling; Andrew Sandor; John Hoult; Nigel McKenzie; Ian R White; Marie Thompson; Paul Bebbington
Journal:  BMJ       Date:  2005-08-15

9.  A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia.

Authors:  Mary F Brunette; Ree Dawson; Christopher D O'Keefe; Meera Narasimhan; Douglas L Noordsy; Joanne Wojcik; Alan I Green
Journal:  J Dual Diagn       Date:  2011

10.  Further support for the role of dysfunctional attitudes in models of real-world functioning in schizophrenia.

Authors:  William P Horan; Yuri Rassovsky; Robert S Kern; Junghee Lee; Jonathan K Wynn; Michael F Green
Journal:  J Psychiatr Res       Date:  2009-12-14       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.